Vitamin D as an early predictor of multiple sclerosis activity and progression - PubMed (original) (raw)
doi: 10.1001/jamaneurol.2013.5993.
Kassandra L Munger 1, Rick White 2, Karl Köchert 3, Kelly Claire Simon 1, Chris H Polman 4, Mark S Freedman 5, Hans-Peter Hartung 6, David H Miller 7, Xavier Montalbán 8, Gilles Edan 9, Frederik Barkhof 4, Dirk Pleimes 10, Ernst-Wilhelm Radü 11, Rupert Sandbrink 12, Ludwig Kappos 11, Christoph Pohl 13
Affiliations
- PMID: 24445558
- PMCID: PMC4000029
- DOI: 10.1001/jamaneurol.2013.5993
Vitamin D as an early predictor of multiple sclerosis activity and progression
Alberto Ascherio et al. JAMA Neurol. 2014 Mar.
Abstract
Importance: It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes.
Objectives: To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome).
Design, setting, and participants: The Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment study was a randomized trial originally designed to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically isolated syndrome. Serum 25(OH)D concentrations were measured at baseline and 6, 12, and 24 months. A total of 465 of the 468 patients randomized had at least 1 25(OH)D measurement, and 334 patients had them at both the 6- and 12-month (seasonally asynchronous) measurements. Patients were followed up for 5 years clinically and by magnetic resonance imaging.
Main outcomes and measures: New active lesions, increased T2 lesion volume, and brain volume on magnetic resonance imaging, as well as MS relapses and disability (Expanded Disability Status Scale score).
Results: Higher 25(OH)D levels predicted reduced MS activity and a slower rate of progression. A 50-nmol/L (20-ng/mL) increment in average serum 25(OH)D levels within the first 12 months predicted a 57% lower rate of new active lesions (P < .001), 57% lower relapse rate (P = .03), 25% lower yearly increase in T2 lesion volume (P < .001), and 0.41% lower yearly loss in brain volume (P = .07) from months 12 to 60. Similar associations were found between 25(OH)D measured up to 12 months and MS activity or progression from months 24 to 60. In analyses using dichotomous 25(OH)D levels, values greater than or equal to 50 nmol/L (20 ng/mL) at up to 12 months predicted lower disability (Expanded Disability Status Scale score, -0.17; P = .004) during the subsequent 4 years.
Conclusions and relevance: Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
Figures
Figure 1
MS outcomes according to dichotomous serum 25(OH)D levels. A: Probability of conversion to CDMS after 12 months; B) Cumulative number of new active lesions on brain MRI; C: % change in T2 lesion volume from year 1 to year 5 on brain MRI; D: % change in brain volume from year 1 to year 5.
Figure 1
MS outcomes according to dichotomous serum 25(OH)D levels. A: Probability of conversion to CDMS after 12 months; B) Cumulative number of new active lesions on brain MRI; C: % change in T2 lesion volume from year 1 to year 5 on brain MRI; D: % change in brain volume from year 1 to year 5.
Figure 1
MS outcomes according to dichotomous serum 25(OH)D levels. A: Probability of conversion to CDMS after 12 months; B) Cumulative number of new active lesions on brain MRI; C: % change in T2 lesion volume from year 1 to year 5 on brain MRI; D: % change in brain volume from year 1 to year 5.
Figure 1
MS outcomes according to dichotomous serum 25(OH)D levels. A: Probability of conversion to CDMS after 12 months; B) Cumulative number of new active lesions on brain MRI; C: % change in T2 lesion volume from year 1 to year 5 on brain MRI; D: % change in brain volume from year 1 to year 5.
Figure 2
MRI evidence of MS activity (panels A and B) and progression (panel C). A: Rate ratio of new active lesions on brain MRI up to year 5. B: Change of T2 lesion volume on brain MRI from year 1 to year 5 by quintiles of serum 25(OH)D. C: Annualized change in EDSS from 6 months to year 5 by quintiles of serum 25(OH)D.
Figure 2
MRI evidence of MS activity (panels A and B) and progression (panel C). A: Rate ratio of new active lesions on brain MRI up to year 5. B: Change of T2 lesion volume on brain MRI from year 1 to year 5 by quintiles of serum 25(OH)D. C: Annualized change in EDSS from 6 months to year 5 by quintiles of serum 25(OH)D.
Similar articles
- Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A. Fitzgerald KC, et al. JAMA Neurol. 2015 Dec;72(12):1458-65. doi: 10.1001/jamaneurol.2015.2742. JAMA Neurol. 2015. PMID: 26458124 Clinical Trial. - A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M. Soilu-Hänninen M, et al. J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22. J Neurol Neurosurg Psychiatry. 2012. PMID: 22362918 Clinical Trial. - Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial. - Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Filippini G, et al. Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2. Cochrane Database Syst Rev. 2017. PMID: 28440858 Free PMC article. Review. - Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. Scott LJ, et al. CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
Cited by
- The Effectiveness of Vitamin D Intake in Improving Symptoms and Relapses of Multiple Sclerosis: A Systematic Review.
Gill A, Orji C, Reghefaoui M, Peresuodei TS, Thota P, Saavedra Palacios MS, Arcia Franchini AP. Gill A, et al. Cureus. 2024 Sep 3;16(9):e68565. doi: 10.7759/cureus.68565. eCollection 2024 Sep. Cureus. 2024. PMID: 39364460 Free PMC article. Review. - Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?
Lis M, Niedziela N, Adamczyk-Zostawa J, Wierzbicki K, Czuba Z, Zalejska-Fiolka J, Bartman W, Świętek A, Adamczyk-Sowa M. Lis M, et al. Biomedicines. 2024 Jul 17;12(7):1580. doi: 10.3390/biomedicines12071580. Biomedicines. 2024. PMID: 39062153 Free PMC article. - CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis.
Muzio L, Perego J. Muzio L, et al. Int J Mol Sci. 2024 Apr 29;25(9):4865. doi: 10.3390/ijms25094865. Int J Mol Sci. 2024. PMID: 38732082 Free PMC article. Review. - From progression to progress: The future of multiple sclerosis.
Oh J, Giacomini PS, Yong VW, Costello F, Blanchette F, Freedman MS. Oh J, et al. J Cent Nerv Syst Dis. 2024 May 6;16:11795735241249693. doi: 10.1177/11795735241249693. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38711957 Free PMC article. - Vitamin D receptor gene BsmI (rs1544410) polymorphism: role in multiple sclerosis and genotype-phenotype correlations.
Jamoussi M, Alaya F, Jamoussi H, Baraket G, Achouri A, Mahmoud MB, Fray S, Ben Ali N, Messaoud T, Hannachi Salhi A, Fredj M. Jamoussi M, et al. Mol Biol Rep. 2024 Apr 5;51(1):478. doi: 10.1007/s11033-024-09369-w. Mol Biol Rep. 2024. PMID: 38578462
References
- Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007 Oct;62(4):335–346. - PubMed
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006 Mar 2;354(9):942–955. - PubMed
- Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–65. - PubMed
- Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 Dec 20;296(23):2832–2838. - PubMed
- Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012 Nov 20;79(21):2140–2145. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical